Literature DB >> 20590907

Cachexia in pancreatic cancer: new treatment options and measures of success.

Kenneth C H Fearon, Vickie E Baracos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20590907      PMCID： PMC2951820          DOI： 10.1111/j.1477-2574.2010.00178.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN： 1365-182X            Impact factor:   3.647


× No keyword cloud information.
  13 in total

1.  Preoperative body composition is influenced by the stage of operable pancreatic adenocarcinoma but does not predict survival after Whipple's procedure.

Authors:  Alireza Aslani; Anthony J Gill; Paul J Roach; Barry J Allen; Ross C Smith
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

Review 2.  Research methodology: cancer cachexia syndrome.

Authors:  Max Dahele; K C H Fearon
Journal:  Palliat Med       Date:  2004-07       Impact factor: 4.762

3.  Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.

Authors:  Carla M M Prado; Vickie E Baracos; Linda J McCargar; Tony Reiman; Marina Mourtzakis; Katia Tonkin; John R Mackey; Sheryl Koski; Edith Pituskin; Michael B Sawyer
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

4.  A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care.

Authors:  Marina Mourtzakis; Carla M M Prado; Jessica R Lieffers; Tony Reiman; Linda J McCargar; Vickie E Baracos
Journal:  Appl Physiol Nutr Metab       Date:  2008-10       Impact factor: 2.665

5.  Cancer cachexia: developing multimodal therapy for a multidimensional problem.

Authors:  K C H Fearon
Journal:  Eur J Cancer       Date:  2008-03-28       Impact factor: 9.162

6.  Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity.

Authors:  Carla M M Prado; Vickie E Baracos; Linda J McCargar; Marina Mourtzakis; Karen E Mulder; Tony Reiman; Charles A Butts; Andrew G Scarfe; Michael B Sawyer
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

7.  Changes in nutritional status associated with unresectable pancreatic cancer.

Authors:  S J Wigmore; C E Plester; R A Richardson; K C Fearon
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function.

Authors:  Jeannine Bachmann; Knut Ketterer; Christiane Marsch; Kerstin Fechtner; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni
Journal:  BMC Cancer       Date:  2009-07-28       Impact factor: 4.430

9.  Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids.

Authors:  A W G Moses; C Slater; T Preston; M D Barber; K C H Fearon
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

10.  Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

Authors:  P J Ross; S Ashley; A Norton; K Priest; J S Waters; T Eisen; I E Smith; M E R O'Brien
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640
View more
  27 in total

Review 1.  Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms.

Authors:  Paige M Bracci
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 2.  Nutrition in Pancreatic Cancer: A Review.

Authors:  Simone Gärtner; Janine Krüger; Ali A Aghdassi; Antje Steveling; Peter Simon; Markus M Lerch; Julia Mayerle
Journal:  Gastrointest Tumors       Date:  2016-01-08

Review 3.  Leukocyte Telomere Length and Pancreatic Cancer Risk: Updated Epidemiologic Review.

Authors:  Samuel O Antwi; Gloria M Petersen
Journal:  Pancreas       Date:  2018-03       Impact factor: 3.327

4.  Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey.

Authors:  Chao-Feng Chang; Yu-Chen Tseng; Hsin-Hung Huang; Yu-Lueng Shih; Tsai-Yuan Hsieh; Hsuan-Hwai Lin
Journal:  Intern Emerg Med       Date:  2017-12-12       Impact factor: 3.397

Review 5.  Nutritional support and parenteral nutrition in cancer patients: an expert consensus report.

Authors:  J A Virizuela; M Camblor-Álvarez; L M Luengo-Pérez; E Grande; J Álvarez-Hernández; M J Sendrós-Madroño; P Jiménez-Fonseca; M Cervera-Peris; M J Ocón-Bretón
Journal:  Clin Transl Oncol       Date:  2017-10-17       Impact factor: 3.405

6.  Proteomic identification of potential markers of myosteatosis in human urine.

Authors:  Holger Husi; Alisdair MacDonald; Richard J E Skipworth; Janice Miller; Andrew Cronshaw; Kenneth C H Fearon; James A Ross
Journal:  Biomed Rep       Date:  2018-04-25

Review 7.  F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.

Authors:  Ammar Sukari; Irfana Muqbil; Ramzi M Mohammad; Philip A Philip; Asfar S Azmi
Journal:  Semin Cancer Biol       Date:  2016-01-21       Impact factor: 15.707

Review 8.  Cachexia and pancreatic cancer: are there treatment options?

Authors:  Tara C Mueller; Marc A Burmeister; Jeannine Bachmann; Marc E Martignoni
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

9.  Leucine supplementation differentially enhances pancreatic cancer growth in lean and overweight mice.

Authors:  Kristyn A Liu; Laura M Lashinger; Audrey J Rasmussen; Stephen D Hursting
Journal:  Cancer Metab       Date:  2014-03-31

Review 10.  The Pancreas: Causes for Malabsorption.

Authors:  Thilo Hackert; Kerstin Schütte; Peter Malfertheiner
Journal:  Viszeralmedizin       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.